NASDAQ
PAVM
Last Price
US $4.74
Valuation
Financial
Performance
Cash flow to debt coverage
PAVmed Inc. cash flow to debt ratio of -39.00K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
PAVmed Inc.'s free cash flow has decreased 15.39K% from $-33.61M last year to $-5.21B, signaling decreasing performance
Debt-to-equity ratio
PAVmed Inc.'s debt to equity ratio is 0.43, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
PAVmed Inc.'s debt has increased relative to shareholder equity from -12.77 last year to 0.43 today, signaling weakened financials
Net debt to EBITDA
PAVmed Inc. has negative EBITDA, making leverage ratio unreliable
Interest coverage
PAVmed Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Profit margin growth
PAVmed Inc.'s profit margin has decreased (1.75K%) in the last year from 1.33K% to -21.91K%, signaling decreasing performance
Current ratio
PAVmed Inc.'s short-term liabilities of $14.84M exceed its short-term assets of $2.56M, signaling financial risk
Return on assets
PAVmed Inc.'s return on assets of -41.01% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
PAVmed Inc.'s return on equity of -49.65%, is lower than 15.00%, indicating bad performance
Earnings quality
PAVmed Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
PAVmed Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings
Positive free cash flow
PAVmed Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
PAVmed Inc. has negative free cash flow, indicating cash burn
Earnings growth
PAVmed Inc.'s yearly earnings has decreased 98.99% since last year from $39.79M to $401.00K, signaling decreasing performance
Revenue growth
PAVmed Inc.'s yearly revenue has increased 2.27K% since last year from $3.00M to $71.00M, signaling increasing performance
Return on invested capital
ROIC -57.62% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
PAVmed Inc.'s 3-year revenue CAGR of -42.68% is negative, indicating declining revenue over the past 3 years
Revenue consistency
PAVmed Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance
Return on equity consistency
PAVmed Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity
Cash Flow Valuation (DCF)
PAVmed Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
PAVmed Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
EBITDA Valuation
PAVmed Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
PAVmed Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
PAVmed Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.
Price-to-book ratio (FY)
PAVmed Inc. has a price-to-book ratio of 0.30x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
PAVmed Inc. has a price-to-sales ratio of 88.29x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-62.41%
Return on equity
ROIC: -15.94%
Valuation History
-
Price to Earnings
EV/EBITDA: -1.9X
Cash flow
Profit margin
-
EBITDA
58.35%
Cash flow
-66.50%
Fair Value
Market $4.74
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.